SG+I
Y-2024-PT-0285
Phase 2 small_molecule active
Quick answer
SG+I for TNBC, Triple Negative Breast Cancer is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- TNBC, Triple Negative Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active